Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism

Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TransCon PTH (Primary)
  • Indications Hypoparathyroidism
  • Focus Therapeutic Use
  • Acronyms PaTH Forward
  • Sponsors Ascendis Pharma
  • Most Recent Events

    • 14 Nov 2019 According to an Ascendis Pharma media release, top-line data from this study is expected in first quarter of 2020.
    • 14 Nov 2019 According to an Ascendis Pharma media release, the company has addendum the protocol to include the subjects previously treated with NATPARA (parathyroid hormone). Previouly before amendment, patients treated with NATPARA were required to undergo a long washout period prior to entering screening in this study. As a result of this amendment, the company will exceed the targeted enrolment of 40.
    • 05 Sep 2019 Planned initiation date changed from 1 Aug 2019 to 1 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top